DTx startup Akili Interactive announced the results of new research at the Meeting of the American College of Neuropsychopharmacology that demonstrates a “strong correlation” between use of the company’s video game-like AKL-T03 treatment program and improved cognitive functions for people living with major depressive disorder (MDD).

The research also showed improvements in patients’ depressive symptoms and overall quality of life, though there wasn’t a significant difference from the control group regarding these metrics. MDD affects more than 16 million adults in the US and is the leading cause of disability for people aged 15 to 44, per the Anxiety and Depression Association of America, which means there’s a massive potential market for Akili’s unique, video game-like treatment programs.

And depression isn’t the only condition Akili is working to address: The company is currently in the process of securing FDA clearance for its game-based treatment for children with ADHD, which could find success among parents who are still nervous about medicating children for behavioral health issues.